Members of the Emergence community are invited to a special BioNetworking event, taking place in Charlottetown, PEI on July 9, 2018.
This special event will take place as part of the at NeuroConX 2018 conference.
Between 10:30am and 1:00pm (including lunch), hear four Industry Spotlight Presentations focused on advancing therapeutics around the Microbiome.
The theme of this year’s NeuroConX Conference is “Mind Your Gut: The Role of the Gut Microbiome in Brain Health and Disease.”
Leading experts will discuss the latest scientific findings around microbiome effects in various brain disorders, including Parkinson’s disease, Alzheimer’s disease, ALS, autism, schizophrenia, and depression. Industry leaders will discuss ways in which innovators are harnessing the human microbiome and advancing novel therapeutics and diagnostics.
WHERE: Prince Edward Island Convention Centre (Delta Prince Edward), 4 Queen Street, Charlottetown, PEI. Archibald-Campbell Room (Harbourview Area)
10:30 am – 12:00 pm: Industry Spotlight Presentations
12:00 – 1:00pm: Lunch
(Free admission)
Speakers:
Caroline Popper, MD, MPH
CEO, Diversigen
Caroline Popper MD, MPH is the CEO of Diversigen, a leading microbiome service and data company. Originally an internist and pathologist, she combines her medical and scientific perspective with knowledge gained from managing a wide spectrum of life sciences businesses in both Fortune 500 and start-up settings in the US and globally. She maintains a large venture and private equity network, sits on several company boards, and speaks internationally on healthcare innovation and value analysis. Dr. Popper received her medical degree from the University of the Witwatersrand (South Africa) and her M.P.H. from Johns Hopkins University (Baltimore). She completed her residencies in internal medicine and in pathology at Johns Hopkins.
Brian Klein, PhD
Senior Scientist, Vendanta Biosciences
Dr. Brian Klein is a Staff Scientist and Microbiology Platform Lead at Vedanta Biosciences in Cambridge, Massachusetts. At Vedanta, Brian leads the isolation and characterization of microbial strains from healthy donors which become part of our industry-leading Culture Collection, as well as downstream high-throughput screening of the Culture Collection. Vedanta designs medicines based on consortia of human commensal bacteria to treat disease, using insights from microbial ecology, mucosal immunology, and human interventional studies. Our platform enables identification of defined bacterial consortia with drug-like properties and their manufacture to GMP standards.
Phillip Strandwitz, PhD
CEO, Holobiome
Phillip Strandwitz is CEO of Holobiome, a company he co-founded to translate microbiome science into novel therapeutics to treat diseases of the central and enteric nervous systems. Holobiome announced an early stage research collaboration with Johnson & Johnson Innovation LLC, Johnson & Johnson Consumer Inc. and Janssen Research & Development, LLC in early 2018, is currently sponsored by Amgen for wet lab space at LabCentral in Cambridge, MA.
Amy Pooler, PhD
Brain Health Specialist, Nestle Institute of Health Sciences
Amy Pooler is a Brain Health Specialist at the Nestlé Research Center, located in Lausanne, Switzerland. Dr. Pooler has been with Nestlé Institute of Health Sciences since July 2014. The Research Center is part of Nestlé’s extensive R&D network, and plays a lead role in breaking new scientific ground in the field of personalized science-based nutrition for the maintenance of health and prevention of chronic disease.